A NOVEL NON-INVASIVE LIQUID BIOPSY TEST FOR MONITORING OF AGGRESSIVE LYMPHOMA
LymFollow is an innovative diagnostic kit under development, for monitoring treatment response and relapse prediction in aggressive Non-Hodgkin's Lymphoma patients .
This advanced solution utilizes a single blood-based biomarker and is conducted on standard lab equipment without requiring any gene sequencing or methylation tests.
LYMPHOMA CURRENT STANDARD OF CARE
Lymphoma, the 5th most prevalent blood cancer, lacks reliable biomarkers for monitoring treatment response and detecting early recurrence. This gap is critical, as some patients fail to achieve complete remission after initial treatment, and approximately 30% face relapse risk.
While PET/CT imaging remains the diagnostic gold standard for evaluation and follow-up, clinical guidelines discourage frequent scans due to radiation exposure risks and limited predictive value for disease relapse.
NOVEL PROMISE THROUGH INNOVATIVE TECHNOLOGY
The innovative LymFollow kit leveraging the discovery of elevated Fibrinogen-like protein (FGL2) activity in peripheral blood cells of patients with malignancies, represents a breakthrough in lymphoma monitoring and management.
This biomarker is suited for early identification of refractory patients who are resistant to first-line therapy - a critical capability currently unavailable before PET/CT evaluation at 6 months.
Early detection is vital, as unidentified refractory patients who complete first-line chemotherapy experience increased tumor mass and T-cell exhaustion, compromising the efficacy of second-line treatments like CAR-T therapy and reducing overall survival rates.
LymFollow's potential ability to identify treatment resistance early can allow for timely transition to second-line therapies, potentially improving treatment outcomes.
In clinical studies, LymFollow has proven effective as a non-invasive tool for monitoring therapy response and detecting relapse in Non-Hodgkin Lymphoma (NHL) patients. This enables healthcare providers to optimize treatment strategies while reducing costs through more targeted and timely interventions.
